Drug
CS 1008
CS 1008: highest development phase Phase 2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| CS-1008 NCT00991796 | Phase 2 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow CS 1008 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.